IVA vs. PHAT, ESPR, ANAB, GHRS, SIGA, TKNO, ZVRA, ATXS, PRTC, and MBX
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Phathom Pharmaceuticals (PHAT), Esperion Therapeutics (ESPR), AnaptysBio (ANAB), GH Research (GHRS), SIGA Technologies (SIGA), Alpha Teknova (TKNO), Zevra Therapeutics (ZVRA), Astria Therapeutics (ATXS), PureTech Health (PRTC), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.
Inventiva vs.
Phathom Pharmaceuticals (NASDAQ:PHAT) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.
Phathom Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
In the previous week, Inventiva had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 1 mentions for Inventiva and 0 mentions for Phathom Pharmaceuticals. Inventiva's average media sentiment score of 0.75 beat Phathom Pharmaceuticals' score of 0.00 indicating that Inventiva is being referred to more favorably in the news media.
Inventiva has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%.
Inventiva has higher revenue and earnings than Phathom Pharmaceuticals.
Phathom Pharmaceuticals presently has a consensus price target of $23.00, suggesting a potential upside of 238.73%. Inventiva has a consensus price target of $13.25, suggesting a potential upside of 510.60%. Given Inventiva's higher probable upside, analysts plainly believe Inventiva is more favorable than Phathom Pharmaceuticals.
99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 24.1% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Phathom Pharmaceuticals received 69 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 72.36% of users gave Phathom Pharmaceuticals an outperform vote.
Summary
Inventiva beats Phathom Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inventiva Competitors List
Related Companies and Tools
This page (NASDAQ:IVA) was last updated on 1/21/2025 by MarketBeat.com Staff
